

Christopher P Fox

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5421777/publications.pdf>

Version: 2024-02-01

52
papers

1,997
citations

279798

23
h-index

265206

42
g-index

53
all docs

53
docs citations

53
times ranked

2331
citing authors

#	ARTICLE	IF	CITATIONS
1	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology</i> , 2016, 3, e217-e227.	4.6	442
2	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology</i> , 2017, 4, e510-e523.	4.6	258
3	Guidelines for the diagnosis and management of primary central nervous system diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 348-363.	2.5	104
4	Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 3589-3596.	7.0	80
5	Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project. <i>Lancet Haematology</i> , 2020, 7, e284-e294.	4.6	78
6	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	1.2	68
7	A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. <i>Blood</i> , 2010, 116, 3695-3704.	1.4	63
8	Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice. <i>Clinical Cancer Research</i> , 2019, 25, 4264-4270.	7.0	61
9	Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties. <i>Bone Marrow Transplantation</i> , 2019, 54, 44-52.	2.4	59
10	Rituximab in primary central nervous system lymphoma—A systematic review and meta-analysis. <i>Hematological Oncology</i> , 2019, 37, 548-557.	1.7	54
11	MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e110-e121.	4.6	54
12	Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK-wide analysis. <i>British Journal of Haematology</i> , 2019, 185, 656-669.	2.5	53
13	Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study. <i>Nature Cancer</i> , 2022, 3, 552-564.	13.2	51
14	Standard-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity. <i>British Journal of Haematology</i> , 2019, 187, 185-194.	2.5	49
15	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients. <i>Blood</i> , 2022, 139, 2499-2511.	1.4	42
16	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system—an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020, 189, 879-887.	2.5	41
17	High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in patients from the Western hemisphere: a study from the European Society for Blood and Marrow Transplantation. <i>Leukemia and Lymphoma</i> , 2015, 56, 3295-3300.	1.3	39
18	Kinetics of T-cell subset reconstitution following treatment with bendamustine and rituximab for low-grade lymphoproliferative disease: a population-based analysis. <i>British Journal of Haematology</i> , 2019, 184, 957-968.	2.5	39

#	ARTICLE	IF	CITATIONS
19	Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery. <i>Blood Advances</i> , 2020, 4, 3586-3593.	5.2	36
20	The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper. <i>British Journal of Haematology</i> , 2020, 190, 708-714.	2.5	36
21	Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. <i>British Journal of Haematology</i> , 2020, 190, 394-404.	2.5	27
22	Impact of Pretransplantation 18 F-Fluorodeoxyglucose-Positron Emission Tomography on Survival Outcomes after T Cell-Depleted Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1234-1241.	2.0	26
23	A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL. <i>Blood Advances</i> , 2019, 3, 1568-1573.	5.2	26
24	Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells. <i>Blood</i> , 2021, 137, 203-215.	1.4	24
25	Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL. <i>Blood Advances</i> , 2022, 6, 2920-2926.	5.2	20
26	The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 918-923.	2.5	19
27	Frontline management of posttransplantation lymphoproliferative disorder in adult solid organ recipient patients – A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2021, 193, 727-740.	2.5	16
28	Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. <i>Blood Advances</i> , 2021, 5, 2229-2236.	5.2	14
29	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021, 138, 181-181.	1.4	14
30	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. <i>Blood</i> , 2016, 128, 511-511.	1.4	13
31	Real-world Outcomes With Rituximab-based Therapy for Posttransplant Lymphoproliferative Disease Arising After Solid Organ Transplant. <i>Transplantation</i> , 2020, 104, 2582-2590.	1.0	12
32	Guidelines for the management of mature T and natural killer cell lymphomas (excluding cutaneous) Tj ETQq0 0 0 rgBT /Overlock 10 196, 507-522.	2.5	12
33	A phase I/II study of thiotepa-based immunochemotherapy in relapsed/refractory primary CNS lymphoma: the TIER trial. <i>Blood Advances</i> , 2021, 5, 4073-4082.	5.2	9
34	Comparative analysis of targeted novel therapies in relapsed, refractory chronic lymphocytic leukaemia. <i>Haematologica</i> , 2020, 106, 284-287.	3.5	8
35	Improved survival outcomes despite older age at diagnosis: an era-by-era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. <i>British Journal of Haematology</i> , 2021, 195, 561-570.	2.5	7
36	The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naïve patients with peripheral T-cell lymphoma: a systematic review of the literature. <i>British Journal of Haematology</i> , 2017, 178, 476-479.	2.5	6

#	ARTICLE	IF	CITATIONS
37	Extended follow-up of CD4 ⁺ T cell recovery kinetics in a large cohort of patients with B-cell lymphoproliferative disease treated with rituximab+bendamustine. <i>Hematological Oncology</i> , 2021, 39, 137-140.	1.7	6
38	Interpretation of retrospective data evaluating high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma; caution required. <i>American Journal of Hematology</i> , 2021, 96, E338-E339.	4.1	5
39	Rare central nervous system lymphomas. <i>British Journal of Haematology</i> , 2022, 197, 662-678.	2.5	5
40	Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood tests during long-term treatment: cohort study using data from the Clinical Practice Research Datalink Gold and Aurum. <i>Rheumatology</i> , 2022, 61, 2783-2791.	1.9	4
41	Single-center Series of Bone Marrow Biopsy-Defined Large Granular Lymphocyte Leukemia: High Rates of Sustained Response to Oral Methotrexate. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 705-712.	0.4	3
42	Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. <i>Bone Marrow Transplantation</i> , 2021, 56, 692-695.	2.4	3
43	Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. <i>Advances in Therapy</i> , 2021, 38, 3789-3802.	2.9	3
44	Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial. <i>Haematologica</i> , 2020, 105, 2868-2871.	3.5	2
45	Attainment of Complete Remission Is Significantly Associated with Longer Survival Outcomes in Relapsed/Refractory (R/R) CLL: A Meta-Analysis. <i>Blood</i> , 2016, 128, 2045-2045.	1.4	2
46	Does end-of-treatment ^{FDG}PET provide any additional prognostic value to the pre-treatment ^{NCCN}IPI score? Reply to Adams and Kwee. <i>British Journal of Haematology</i> , 2017, 177, 320-321.	2.5	1
47	A comparison of bendamustine-EAM versus BEAM conditioning for autologous stem cell transplant in lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 3529-3531.	1.3	1
48	Survival outcomes for extranodal natural-killer T-cell lymphoma – Authors' reply. <i>Lancet Haematology</i> , 2020, 7, e442.	4.6	1
49	Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Icicle Extension Study. <i>Blood</i> , 2016, 128, 2049-2049.	1.4	1
50	Refining CNS relapse risk in DLBCL: easy as ABC?. <i>Blood</i> , 2019, 133, 886-888.	1.4	0
51	American Society of Hematology 2020 Podcast Collection: FL and DLBCL. <i>Advances in Therapy</i> , 2021, 38, 8-15.	2.9	0
52	BEAM-Campath Allogeneic Stem Cell Transplantation for Aggressive Non-Hodgkin's Lymphomas. An Analysis of Outcomes From the BSBMT. <i>Blood</i> , 2012, 120, 2039-2039.	1.4	0